In Vitro Diagnostics Regulation Explained

Diagnostic tests are essential tools in modern healthcare, guiding clinical decisions ranging from routine check-ups to complex treatments. Tests performed on biological samples outside the living body—such as blood, saliva, or tissue—are known as In Vitro Diagnostics (IVDs). Because these tests directly influence medical decisions, their design, manufacture, and performance are tightly controlled by health regulators worldwide. Understanding how these tests are classified and monitored helps explain why some are available on pharmacy shelves while others are restricted to highly specialised laboratories.

Understanding In Vitro Diagnostics

In vitro diagnostics are medical devices intended to examine specimens derived from the human body. These devices range from simple items like blood glucose meters and home pregnancy tests to complex automated laboratory systems used to detect infectious diseases, genetic mutations, or cancer markers. Unlike medicines, which act chemically inside the body to treat a condition, IVDs provide information by measuring or identifying specific substances in a sample. Regulators oversee these products to ensure they are analytically valid—meaning they correctly detect or measure the target—and clinically valid, meaning the target is relevant to the health condition being assessed. In South Africa, the South African Health Products Regulatory Authority (SAHPRA) is responsible for registering and regulating these diagnostic devices.

Risk-Based Classification

Regulators globally generally classify IVDs based on the risk associated with an incorrect result. A test that could lead to a life-threatening misdiagnosis or a contaminated blood supply is subject to far stricter scrutiny than a test for a minor, self-limiting condition. The World Health Organization and many national regulators use a four-tier risk system, often labelled Class A through D. Class A represents the lowest risk, including general laboratory equipment and specimen receptacles that do not directly determine a diagnosis. Class B and C include tests for moderate to high-risk conditions, such as sexually transmitted infections or genetic screening. Class D represents the highest risk, encompassing tests used to screen blood for HIV or hepatitis, or to detect highly fatal and transmissible diseases. Higher-risk classes typically require more rigorous clinical evidence, factory inspections, and ongoing regulatory oversight before they can be marketed.

The Shift to Self-Testing

Historically, most complex IVDs were restricted to use by trained laboratory professionals. However, the push for greater healthcare access, highlighted by the rise of HIV self-tests and, more recently, rapid COVID-19 antigen tests, brought IVDs directly into the hands of the general public. This shift raised unique regulatory questions. Regulators had to evaluate not just the test's biological accuracy in a lab, but its usability by an untrained individual in a real-world setting. This includes assessing whether the instructions are easily understood, the sample collection method is safe and reliable for a layperson, and the results can be interpreted without professional guidance. The pandemic accelerated the emergency authorisation of many self-tests, leading regulators to rapidly refine their frameworks for evaluating at-home diagnostics while balancing the need for public access against the risks of false results.

Quality Assurance and Post-Market Surveillance

Regulatory approval is only the first step in an IVD's lifecycle. Maintaining quality assurance requires continuous oversight throughout the product's lifespan. Manufacturers must adhere to Good Manufacturing Practices to ensure each batch of tests performs identically to the clinical samples originally evaluated. Once a test is on the market, regulators rely on post-market surveillance to identify emerging problems. If a particular batch of tests begins producing inaccurate results due to a manufacturing flaw, a transport issue, or the emergence of a new viral variant, the manufacturer or regulator may issue a recall. Healthcare professionals and, in some systems, consumers can report faulty test results to national pharmacovigilance or medical device reporting programmes. Verifying that a diagnostic test is registered with the relevant authority—such as checking for SAHPRA registration in South Africa or searching for registered medical devices via HealthSA—helps ensure that the product has met these baseline quality and safety standards.